SrasV1, Main, Exploration, bibRecord, 005D27

Treatment of SARS with human interferons.

Identifieur interne : 005D27 ( Main/Exploration ); précédent : 005D26; suivant : 005D28

Treatment of SARS with human interferons.

Auteurs : J. Cinatl [Allemagne] ; B. Morgenstern ; G. Bauer ; P. Chandra ; H. Rabenau ; H W Doerr

Source :

Lancet (London, England) [ 1474-547X ] ; 2003.

RBID : pubmed:12892961

Descripteurs français

KwdFr :
- Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Coronavirus (), Coronavirus (isolement et purification), Humains, Interféron alpha (usage thérapeutique), Interféron bêta (usage thérapeutique), Interféron gamma (usage thérapeutique), Interférons (usage thérapeutique), Protéines recombinantes (usage thérapeutique), Réplication virale (), Résultat thérapeutique, Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus de la stomatite vésiculeuse de type Indiana ().
MESH :
- isolement et purification : Coronavirus.
- pharmacologie : Antiviraux.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Interféron alpha, Interféron bêta, Interféron gamma, Interférons, Protéines recombinantes.
- virologie : Syndrome respiratoire aigu sévère.
- Coronavirus, Humains, Réplication virale, Résultat thérapeutique, Virus de la stomatite vésiculeuse de type Indiana.

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Coronavirus (classification), Coronavirus (drug effects), Coronavirus (isolation & purification), Humans, Interferon-alpha (therapeutic use), Interferon-beta (therapeutic use), Interferon-gamma (therapeutic use), Interferons (therapeutic use), Recombinant Proteins (therapeutic use), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Treatment Outcome, Vesicular stomatitis Indiana virus (drug effects), Virus Replication (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Interferon-beta, Interferon-gamma, Interferons, Recombinant Proteins.
- classification : Coronavirus.
- drug effects : Coronavirus, Vesicular stomatitis Indiana virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- isolation & purification : Coronavirus.
- virology : Severe Acute Respiratory Syndrome.
- Humans, Treatment Outcome.

Abstract

Effective antiviral agents are needed to treat severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons against two clinical isolates of SARS-CoV--FFM-1, from Frankfurt patients, and Hong Kong--replicated in Vero and Caco2 cells. Interferon beta was five to ten times more effective in Caco2 cells. Interferon alpha effectively inhibited SARS-CoV replication, but with a selectivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in Vero cell cultures, but was completely ineffective in Caco2 cell cultures. Interferon beta could be useful alone or in combination with other antiviral drugs for the treatment of SARS.

DOI: 10.1016/s0140-6736(03)13973-6
PubMed: 12892961

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of SARS with human interferons.</title>
<author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de </nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
</author>
<author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
</author>
<author><name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
</author>
<author><name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12892961</idno>
<idno type="pmid">12892961</idno>
<idno type="doi">10.1016/s0140-6736(03)13973-6</idno>
<idno type="wicri:Area/PubMed/Corpus">003246</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003246</idno>
<idno type="wicri:Area/PubMed/Curation">003246</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003246</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003005</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003005</idno>
<idno type="wicri:Area/Ncbi/Merge">000266</idno>
<idno type="wicri:Area/Ncbi/Curation">000266</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000266</idno>
<idno type="wicri:Area/Main/Merge">006198</idno>
<idno type="wicri:Area/Main/Curation">005D27</idno>
<idno type="wicri:Area/Main/Exploration">005D27</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of SARS with human interferons.</title>
<author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de </nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
</author>
<author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
</author>
<author><name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
</author>
<author><name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
</analytic>
<series><title level="j">Lancet (London, England)</title>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Coronavirus (classification)</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus (isolation & purification)</term>
<term>Humans</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Interferon-beta (therapeutic use)</term>
<term>Interferon-gamma (therapeutic use)</term>
<term>Interferons (therapeutic use)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Treatment Outcome</term>
<term>Vesicular stomatitis Indiana virus (drug effects)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Coronavirus ()</term>
<term>Coronavirus (isolement et purification)</term>
<term>Humains</term>
<term>Interféron alpha (usage thérapeutique)</term>
<term>Interféron bêta (usage thérapeutique)</term>
<term>Interféron gamma (usage thérapeutique)</term>
<term>Interférons (usage thérapeutique)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Réplication virale ()</term>
<term>Résultat thérapeutique</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus de la stomatite vésiculeuse de type Indiana ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
<term>Interferon-gamma</term>
<term>Interferons</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
<term>Vesicular stomatitis Indiana virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
<term>Interféron gamma</term>
<term>Interférons</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coronavirus</term>
<term>Humains</term>
<term>Réplication virale</term>
<term>Résultat thérapeutique</term>
<term>Virus de la stomatite vésiculeuse de type Indiana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective antiviral agents are needed to treat severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons against two clinical isolates of SARS-CoV--FFM-1, from Frankfurt patients, and Hong Kong--replicated in Vero and Caco2 cells. Interferon beta was five to ten times more effective in Caco2 cells. Interferon alpha effectively inhibited SARS-CoV replication, but with a selectivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in Vero cell cultures, but was completely ineffective in Caco2 cell cultures. Interferon beta could be useful alone or in combination with other antiviral drugs for the treatment of SARS.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>District de Darmstadt</li>
<li>Hesse (Land)</li>
</region>
<settlement><li>Francfort-sur-le-Main</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name>
<name sortKey="Chandra, P" sort="Chandra, P" uniqKey="Chandra P" first="P" last="Chandra">P. Chandra</name>
<name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
<name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B" last="Morgenstern">B. Morgenstern</name>
<name sortKey="Rabenau, H" sort="Rabenau, H" uniqKey="Rabenau H" first="H" last="Rabenau">H. Rabenau</name>
</noCountry>
<country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D27 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D27 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:12892961
   |texte=   Treatment of SARS with human interferons.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:12892961" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Treatment of SARS with human interferons.

Treatment of SARS with human interferons.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.